MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/hematolrep16040075

Медицинская библиотека · Hematology reports · 2024

Venetoclax Plus Intensified Chemoimmunotherapy as a Bridge to Allogeneic Stem Cell Transplantation in Richter Syndrome: Report of Two Cases.

Derenzini Enrico, Cignetti Alessandro, Tabanelli Valentina, Gottardi Daniela, Gerbino Elvira, Vanazzi Anna, Sammassimo Simona, Maraglino Alessio Maria Edoardo, Melle Federica, Motta Giovanna, Malengo Daniela, Omodeo Salè Emanuela, Bonello Lisa, Pastano Rocco, Pileri Stefano, Carnevale Schianca Fabrizio, Tarella Corrado

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

Background

Richter syndrome (RS) represents a major unmet need in the lymphoma field, being refractory to chemoimmunotherapy and targeted agents. The BCL-2 inhibitor venetoclax in combination with dose-adjusted EPOCH-R chemoimmunotherapy showed promising efficacy in patients affected by RS. However, responses were not durable, suggesting the need for further treatment optimization.

Methods

Here, we report two cases of RS achieving long-term complete remission with intensified chemoimmunotherapy (Rituximab-G-MALL B-ALL/NHL2002 regimen) plus venetoclax induction, followed by haploidentical hematopoietic stem cell transplant (allo-HSCT). Venetoclax was given continuously for 14 consecutive days after every Rituximab-G-MALL cycle in off-label use. An accelerated venetoclax rump-up schedule was used in both patients to reach the maximal dose. Maximal venetoclax dose was 300 mg and 400 mg in patient 1 and patient 2, respectively.

Results

The combined treatment was well tolerated, with no major infective complications or non-hematological toxicities. In both patients, immunosuppression was discontinued within day 180 after transplant with no graft-versus-host-disease flares. Both patients are alive and in continuous complete remission after 60 and 72 months following allo-HSCT.

Conclusions

This report supports the feasibility of a combination treatment with BCL-2 inhibitors and intensive chemoimmunotherapy as a bridge to allo-HSCT in RS.

Для цитирования: Derenzini Enrico, Cignetti Alessandro, Tabanelli Valentina, Gottardi Daniela, Gerbino Elvira, Vanazzi Anna, Sammassimo Simona, Maraglino Alessio Maria Edoardo, Melle Federica, Motta Giovanna, Malengo Daniela, Omodeo Salè Emanuela, Bonello Lisa, Pastano Rocco, Pileri Stefano, Carnevale Schianca Fabrizio, Tarella Corrado. Venetoclax Plus Intensified Chemoimmunotherapy as a Bridge to Allogeneic Stem Cell Transplantation in Richter Syndrome: Report of Two Cases.. Hematology reports. 2024. DOI: 10.3390/hematolrep16040075.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.